Study S001528

A Randomized Controlled Study Assessing the Effect of Liraglutide on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes Mellitus: The LIraglutide and Beta-cell RepAir (LIBRA) Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01270789
Acronym: LIBRA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 63
Start: 2011-01
Primary completion: 2013-12
Lead sponsor: Mount Sinai Hospital, Canada
Conditions: Type 2 Diabetes
Interventions: DRUG:Liraglutide; DRUG:placebo
Results posted: FALSE

Registered primary outcomes

Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2) [48-weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025639	Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion. Kramer CK, The Journal of clinical endocrinology and metabolism	2017	Randomized trial	PMID 28472325 DOI	cites ClinicalTrials.gov:NCT01270789; registry reference DERIVED:28472325
R0026378	The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. Kramer CK, The Journal of clinical endocrinology and metabolism	2015	Randomized trial	PMID 26230296 DOI	cites ClinicalTrials.gov:NCT01270789; registry reference DERIVED:26230296
R0026414	Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Retnakaran R, Diabetes care	2014	Randomized trial	PMID 25249651 DOI	cites ClinicalTrials.gov:NCT01270789; registry reference DERIVED:25249651